MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41467-024-45358-0

Медицинская библиотека · Nature communications · 2024

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.

Bol Kalijn F, Schreibelt Gerty, Bloemendal Martine, van Willigen Wouter W, Hins-de Bree Simone, de Goede Anna L, de Boer Annemiek J, Bos Kevin J H, Duiveman-de Boer Tjitske, Olde Nordkamp Michel A M, van Oorschot Tom G M, Popelier Carlijn J, Pots Jeanne M, Scharenborg Nicole M, van de Rakt Mandy W M M, de Ruiter Valeska, van Meeteren Wilmy S, van Rossum Michelle M, Croockewit Sandra J, Koeneman Bouke J, Creemers Jeroen H A, Wortel Inge M N, Angerer Caroline, Brüning Mareke, Petry Katja, Dzionek Andrzej, van der Veldt Astrid A, van Grünhagen Dirk J, Werner Johanna E M, Bonenkamp Johannes J, Haanen John B A G, Boers-Sonderen Marye J, Koornstra Rutger H T, Boomsma Martijn F, Aarntzen Erik H J, Gotthardt Martin, Nagarajah James, de Witte Theo J M, Figdor Carl G, de Wilt Johannes H W, Textor Johannes, de Groot Jan Willem B, Gerritsen Winald R, de Vries I Jolanda M

Рандомизированное исследованиеКлиническое исследование III фазыСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were randomized to adjuvant treatment with nDCs (n = 99) or placebo (n = 49). Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens. The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas the secondary endpoints included median RFS, 2-year and median overall survival, adverse event profile, and immunological response The 2-year RFS rate was 36.8% in the nDC treatment group and 46.9% in the control group (p = 0.31). Median RFS was 12.7 months vs 19.9 months, respectively (hazard ratio 1.25; 90% CI: 0.88-1.79; p = 0.29). Median overall survival was not reached in both treatment groups (hazard ratio 1.32; 90% CI: 0.73-2.38; p = 0.44). Grade 3-4 study-related adverse events occurred in 5% and 6% of patients. Functional antigen-specific T cell responses could be detected in 67.1% of patients tested in the nDC treatment group vs 3.8% of patients tested in the control group (p < 0.001). In conclusion, while adjuvant nDC treatment in stage IIIB/C melanoma patients generated specific immune responses and was well tolerated, no benefit in RFS was observed.

Для цитирования: Bol Kalijn F, Schreibelt Gerty, Bloemendal Martine, van Willigen Wouter W, Hins-de Bree Simone, de Goede Anna L, de Boer Annemiek J, Bos Kevin J H, Duiveman-de Boer Tjitske, Olde Nordkamp Michel A M, van Oorschot Tom G M, Popelier Carlijn J, Pots Jeanne M, Scharenborg Nicole M, van de Rakt Mandy W M M, de Ruiter Valeska, van Meeteren Wilmy S, van Rossum Michelle M, Croockewit Sandra J, Koeneman Bouke J, Creemers Jeroen H A, Wortel Inge M N, Angerer Caroline, Brüning Mareke, Petry Katja, Dzionek Andrzej, van der Veldt Astrid A, van Grünhagen Dirk J, Werner Johanna E M, Bonenkamp Johannes J, Haanen John B A G, Boers-Sonderen Marye J, Koornstra Rutger H T, Boomsma Martijn F, Aarntzen Erik H J, Gotthardt Martin, Nagarajah James, de Witte Theo J M, Figdor Carl G, de Wilt Johannes H W, Textor Johannes, de Groot Jan Willem B, Gerritsen Winald R, de Vries I Jolanda M. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.. Nature communications. 2024. DOI: 10.1038/s41467-024-45358-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.